Patents by Inventor Walter Fast

Walter Fast has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
    Patent number: 11021469
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, Board of Regents, The University of Texas System
    Inventors: Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
  • Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same
    Patent number: 10626087
    Abstract: Indoline and tetrahydroquinoline sulfonyl compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (“MBLs”), such as NDM-1 are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the compounds disclosed herein.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: April 21, 2020
    Assignees: LOYOLA UNIVERSITY OF CHICAGO, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Daniel Paul Becker, Cory Reidl, Maxwell Moore, Tahirah K. Heath, Walter Fast
  • INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME
    Publication number: 20190337931
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 7, 2019
    Inventors: Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
  • INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME
    Publication number: 20190084932
    Abstract: Indoline and tetrahydroquinoline sulfonyl compounds that can inhibit DapE and/or bacterial metallo-62 -lactamases (“MBLs”), such as NDM-1 are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the compounds disclosed herein.
    Type: Application
    Filed: July 11, 2016
    Publication date: March 21, 2019
    Inventors: Daniel Paul Becker, Cory Reidl, Maxwell Moore, Tahirah K. Heath, Walter Fast
  • INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME
    Publication number: 20170226090
    Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Daniel Paul Becker, Richard C. Holz, Tahirah K. Heath, Cory Reidl, Anna Starus, Walter Fast
  • Compositions And Methods For Engineered Human Arginine Deiminases
    Publication number: 20090238813
    Abstract: The present invention discloses the engineering of a human enzyme with arginine hydrolytic activity suitable for human therapy. An enzyme comprising of a human sequence is not likely to induce adverse immunological responses and thus is expected to constitute a superior therapeutic. Since the human genome does not encode arginases with the proper high affinity catalytic properties (i.e., for example, a low Km and high catalytic activity, kcat) an appropriate arginase can be engineered by modifying an enzyme with related catalytic activity. For example, the human enzyme PAD4 can hydrolyze arginine in peptide substrates but does not have activity for free arginine. First, a high throughput assay was developed for detecting arginine activity by monitoring the formation of the hydrolytic product citrulline. Then, using a combination of rational design and iterative mutation and screening PAD4 mutants were identified and isolated exhibiting high affinity free arginine metabolic activity.
    Type: Application
    Filed: December 3, 2008
    Publication date: September 24, 2009
    Inventors: George Georgiou, Everett Stone, Walter Fast